Nuon Therapeutics, the San Mateo, CA-based developer of treatments for autoimmune diseases, has raised $10 million in a financing composed of debt and option securities, according to a regulatory filing. The document doesn’t say who invested, although its board of directors includes representatives from Domain Associates, Frazier Healthcare Ventures, and GBS Venture Partners. Affymax CEO Arlene Morris is also a director.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
